Also, although the considerations mentioned before are valid for high PSMA expressing PCa lesions, decreasing the MAapp to limit non-specific uptake could also affect the detectability of low PSMA expressing lesions, which could lead to an underestimation of the tumor burden. This evidence concerns the gene FOLH1 and posterior cortical atrophy.